“…However, there are concerns with the effectiveness and tolerability of generics compared with originator drugs [3,7,24,[31][32][33][34][35][36][37], with some originator companies questioning the quality of generics as part of their marketing strategies to reduce the erosion of sales which follow patent loss [38]. Whilst these concerns typically only apply to a minority of situations [34,36,39], as demonstrated for instance by 'dispense as written' prescriptions only accounting for 2.7% of prescriptions written by physicians in the US [30], failure by health authorities, physicians and pharmacists to adequately address these concerns will mean reduced savings in reality [3-5, 17, 40].…”